跳至主要内容
临床试验/NL-OMON56057
NL-OMON56057招募中3 期

Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) an international randomized phase III trial - SUBITO

ederlands Kanker Instituut0 个研究点目标入组 94 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
94

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Women and men with stage III adenocarcinoma of the breast harboring signs of
  • a breast cancer with features of homologous recombination deficiency (HRD)
  • - Age of 18-65 years
  • - The tumor must be HER2-negative
  • - Eastern Cooperative Oncology Group (ECOG) performance status 0-1

排除标准

  • - Distant metastases
  • - Previous radiation therapy
  • - Previous chemotherapy
  • - Any previous treatment with a PARP-inhibitor, including olaparib
  • - Pre-existing neuropathy from any cause in excess of Grade 1
  • - Chronic concomitant use of known strong or moderate CYP3A inducers

研究者

发起方
ederlands Kanker Instituut

相似试验

Substantially improving the cure rate of high-risk... | 临床试验